Xcov­ery nabs first FDA ap­proval for lung can­cer drug

The FDA has ap­proved Xcov­ery Hold­ings’ ALK in­hibitor En­sacove for first-line treat­ment of adults with anaplas­tic lym­phoma ki­nase (ALK)-pos­i­tive lo­cal­ly ad­vanced or metasta­t­ic non-small cell …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER